Viridian Therapeutics, Inc./DE Additional Paid in Capital
Viridian Therapeutics, Inc./DE (VRDN) had Additional Paid in Capital of $2.13 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-06
- 2026-06-30: Additional Paid in Capital $2.13B.
- 2026-03-31: Additional Paid in Capital $1.95B.
- 2025-12-31: Additional Paid in Capital $1.93B.
- 2025-09-30: Additional Paid in Capital $1.53B.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $2.13B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.95B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.93B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.53B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.51B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $1.50B 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $1.48B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.43B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.17B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.16B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $960.54M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $807.34M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $792.07M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $771.71M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $741.07M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $709.79M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $452.70M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $439.19M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $412.10M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $372.29M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $259.79M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $242.30M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $218.09M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $208.62M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $203.29M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $202.69M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $183.90M 10-K · filed 2021-03-26 | $183.57M 10-K · filed 2020-03-13 |
| 2019-09-30 | $180.91M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $179.94M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $178.57M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $177.34M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $176.40M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $174.33M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $170.66M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $131.88M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $125.97M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $122.49M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $121.84M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $5.15M 10-K · filed 2018-03-15 | $30.31M 10-K · filed 2017-03-24 |
| 2016-09-30 | $29.65M 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $29.56M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $28.96M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $28.37M 10-K · filed 2017-03-24 | $28.27M 10-K · filed 2016-03-21 |
| 2015-09-30 | $27.52M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $22.70M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $22.35M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $12.59M 10-K · filed 2016-03-21 | |
| 2014-09-30 | $39.01M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $38.31M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |